Knowledge Gaps and Research Needs for Biologic Therapy in Rhinology Practice

Area of Science:

• Otolaryngology
• Immunology
• Pharmacology

Background:

• Chronic rhinosinusitis with nasal polyposis (CRSwNP) presents a significant challenge in treatment, particularly for patients with recalcitrant disease.
• Biologic agents are an emerging therapeutic class offering new hope for managing severe CRSwNP.
• The heterogeneity of CRSwNP necessitates precise patient stratification for optimal therapeutic outcomes.

Purpose of the Study:

• To review the current landscape and future directions of biologic agents for CRSwNP.
• To emphasize the importance of endotype-specific biomarkers in patient selection and treatment response prediction.
• To highlight the need for comparative trials and health economic evaluations.

Main Methods:

• Literature review of current research and ongoing clinical trials on biologic agents for CRSwNP.
• Analysis of the role of biomarkers in defining CRSwNP endotypes.
• Discussion of future research needs, including head-to-head trials and cost-effectiveness studies.

Main Results:

• Biologic agents demonstrate potential for treating recalcitrant CRSwNP.
• Endotype-specific biomarkers are critical for identifying suitable candidates for biologic therapies.
• Further research is required to compare different biologic agents and assess their cost-effectiveness.

Conclusions:

• Biologic therapies represent a promising advancement in managing CRSwNP.
• Personalized medicine approaches, guided by biomarkers, are essential for maximizing treatment efficacy.
• Future research should focus on comparative effectiveness, real-world evidence, and economic evaluations to guide clinical practice.